Long Daniel D, Aggen James B, Christensen Burton G, Judice J Kevin, Hegde Sharath S, Kaniga Koné, Krause Kevin M, Linsell Martin S, Moran Edmund J, Pace John L
Theravance, Inc., San Francisco, CA 94080, USA.
J Antibiot (Tokyo). 2008 Oct;61(10):595-602. doi: 10.1038/ja.2008.79.
The design, synthesis and antibacterial activity of novel glycopeptide/beta-lactam heterodimers is reported. Employing a multivalent approach to drug discovery, vancomycin and cephalosporin synthons, A and B respectively, were chemically linked to yield heterodimer antibiotics. These novel compounds were designed to inhibit Gram-positive bacterial cell wall biosynthesis by simultaneously targeting the principal cellular targets of both glycopeptides and beta-lactams. The antibiotics 8a-f displayed remarkable potency against a wide range of Gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA). Compound 8e demonstrated excellent bactericidal activity against MRSA (ATCC 33591) and initial evidence supports a multivalent mechanism of action for this important new class of antibiotic.
报道了新型糖肽/β-内酰胺异二聚体的设计、合成及抗菌活性。采用多价药物发现方法,将万古霉素和头孢菌素合成子(分别为A和B)进行化学连接,得到异二聚体抗生素。这些新型化合物旨在通过同时靶向糖肽和β-内酰胺的主要细胞靶点来抑制革兰氏阳性菌细胞壁的生物合成。抗生素8a - f对包括耐甲氧西林金黄色葡萄球菌(MRSA)在内的多种革兰氏阳性菌显示出显著的效力。化合物8e对MRSA(ATCC 33591)表现出优异的杀菌活性,初步证据支持这类重要新型抗生素的多价作用机制。